Ulka N. Vaishampayan

Also affiliated with University of Michigan, The Barbara Ann Karmanos Cancer Institute, Michigan Medicine, Michigan Cancer Research Consortium

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6532896

Top 100%

0DataRank

Top 100%0 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Papers

Driven by 37 papers — median percentile 0. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Nature(2021)10.1038/s41586-021-04246-z

N/A

6.3DataRank · unranked

322 citations

Abhijit Parolia, Yuanyuan Qiao, Pushpinder Bawa, Sanjana Eyunni, Rahul Mannan +33 more

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.34633

N/A

2.0DataRank · unranked

43 citations

Lance K. Heilbrun, Paul Monk, Sheela Tejwani, Guru Sonpavde, Clara Hwang +10 more

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3441

N/A

1.6DataRank · unranked

45 citations

Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh +15 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

Nature Genetics(2025)10.1038/s41588-025-02336-6

N/A

0.449DataRank · unranked

19 citations

Zhixiang Chen, Yuanyuan Qiao, Jean C. Tien, Eleanor Young, Rahul Mannan +24 more

Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients

International Journal of Radiation Oncology*Biology*Physics(2023)10.1016/j.ijrobp.2023.11.024

N/A

0.405DataRank · unranked

7 citations

Lance K. Heilbrun, Nitin Vaishampayan, Felicity W. K. Harper, Dongping Shi, Daryn Smith +10 more

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4546

N/A

0.193DataRank · unranked

2 citations

Catherine M. Tangen, Christopher W. Ryan, Ulka N. Vaishampayan, Brian Shuch, Pedro C. Barata +7 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507

N/A

0DataRank · unranked

1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1601

N/A

0DataRank · unranked

34 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma

European Journal of Radiology Open(2022)10.1016/j.ejro.2022.100440

N/A

0DataRank · unranked

13 citations

Steven Cen, Haris Zahoor, Imran Siddiqui, Manju Aron, Akash Sali +11 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102018

N/A

0DataRank · unranked

26 citations

Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazlı Dizman +23 more

Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype

Cancers(2023)10.3390/cancers15235530

N/A

0DataRank · unranked

13 citations

Srinivas Nallandhighal, Randy Vince, Brittney Cotta, Judith Stangl‐Kremser, Daniel Triner +7 more

Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth

Scientific Reports(2023)10.1038/s41598-023-47633-4

N/A

0DataRank · unranked

8 citations

Diego Sbrissa, Mark Pressprich, Seongho Kim, Arun K. Rishi, Ulka N. Vaishampayan +3 more

Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth

Research Square(2023)10.21203/rs.3.rs-2590830/v1

N/A

0DataRank · unranked

2 citations

Diego Sbrissa, Mark Pressprich, Seongho Kim, Ulka N. Vaishampayan, Michael L. Cher +2 more

Data from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6532896

Top 100%

0DataRank

Top 100%0 citations

Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson +9 more

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0400

N/A

0DataRank · unranked

34 citations

Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng +17 more

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2322563121

N/A

0DataRank · unranked

23 citations

Caleb Cheng, Yuanyuan Qiao, Hanbyul Cho, Eleanor Young, Rahul Mannan +24 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.29.587346

N/A

0DataRank · unranked

11 citations

Zhixiang Chen, Yuanyuan Qiao, Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan +19 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

European Urology(2020)10.1016/j.eururo.2020.06.033

N/A

0DataRank · unranked

79 citations

Pedro Isaacsson Velho, Roberto Nussenzveig, Jonathan Chipman, Víctor Sacristán Santos, Stephanie Erickson +9 more

Defining the Role of Surgical Resection in Metastatic Renal Cell Carcinoma: A Mini Review

European Urology Focus(2025)10.1016/j.euf.2025.04.022

N/A

0DataRank · unranked

0 citations

Simpa S. Salami, Ulka N. Vaishampayan, Todd M. Morgan, Udit Singhal, Steven Monda

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1412

N/A

0DataRank · unranked

8 citations

Eric Laille, Ulka N. Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati +16 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065

N/A

0DataRank · unranked

10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1077

N/A

0DataRank · unranked

7 citations

Hatem Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Münster +11 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.97

N/A

0DataRank · unranked

6 citations

Lawrence G. Lum, Abhinav Deol, Archana Thakur, Elisabeth I. Heath, Wei Chen +4 more

Ulka N. Vaishampayan

Indexed papers

Top data-sharing exemplar

Papers